Greg Wujek has more than 30 years of biopharma experience in roles of increasing responsibility. Currently, he serves as the Chief Commercial Officer at Actum Pharma. Previously, he led the Life Science Industry Consultants at SAS and recently held the role of Chief Commercial Officer at CCB. Previously, Greg served as Chief Executive Officer of Castle Creek Pharmaceuticals, where he led the purchase of Fibrocell Science. Prior to joining Castle Creek, he managed and developed successful strategies for Zimmer Biomet/Biologics Unit, overseeing the launch of their first prescription injectable product, Gel-One®.
Earlier in his career, Greg also led the build-out of Savient’s biologics arm, taking responsibility for sales, market access, and operations in support of EUFLEXXA®, the company’s first biologic launch. Prior to Savient, Greg was also responsible for managing the team that successfully launched ALTOPREV® and FORTAMET® at Andrx Laboratories. Greg began his career at Forest Laboratories, where he quickly advanced and took responsibility for building out the Market Access department in support of the company’s first blockbuster, TIAZAC®.
Greg graduated from Illinois State University with a B.S. in Political Science.